• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用 Kaplan-Meier 估计量的变换进行单臂生存研究的样本量计算。

Sample size calculations for single-arm survival studies using transformations of the Kaplan-Meier estimator.

机构信息

Research Center for Medical and Health Data Science, The Institute of Statistical Mathematics, Tokyo, Japan.

Department of Data Science, The Institute of Statistical Mathematics, Tokyo, Japan.

出版信息

Pharm Stat. 2021 May;20(3):499-511. doi: 10.1002/pst.2090. Epub 2020 Dec 21.

DOI:10.1002/pst.2090
PMID:33347712
Abstract

In single-arm clinical trials with survival outcomes, the Kaplan-Meier estimator and its confidence interval are widely used to assess survival probability and median survival time. Since the asymptotic normality of the Kaplan-Meier estimator is a common result, the sample size calculation methods have not been studied in depth. An existing sample size calculation method is founded on the asymptotic normality of the Kaplan-Meier estimator using the log transformation. However, the small sample properties of the log transformed estimator are quite poor in small sample sizes (which are typical situations in single-arm trials), and the existing method uses an inappropriate standard normal approximation to calculate sample sizes. These issues can seriously influence the accuracy of results. In this paper, we propose alternative methods to determine sample sizes based on a valid standard normal approximation with several transformations that may give an accurate normal approximation even with small sample sizes. In numerical evaluations via simulations, some of the proposed methods provided more accurate results, and the empirical power of the proposed method with the arcsine square-root transformation tended to be closer to a prescribed power than the other transformations. These results were supported when methods were applied to data from three clinical trials.

摘要

在生存结局的单臂临床试验中,Kaplan-Meier 估计量及其置信区间被广泛用于评估生存概率和中位生存时间。由于 Kaplan-Meier 估计量的渐近正态性是一个常见的结果,因此尚未深入研究其样本量计算方法。现有的样本量计算方法是基于 Kaplan-Meier 估计量的渐近正态性,使用对数变换。然而,在小样本量(单臂试验中常见的情况)下,对数变换估计量的小样本性质非常差,并且现有方法使用不适当的标准正态逼近来计算样本量。这些问题会严重影响结果的准确性。在本文中,我们提出了基于有效标准正态逼近的替代方法来确定样本量,这些方法通过几种变换来确定样本量,即使在小样本量的情况下,也可以得到准确的正态逼近。通过模拟进行的数值评估表明,一些提出的方法提供了更准确的结果,并且使用反正弦平方根变换的建议方法的经验功效往往比其他变换更接近规定的功效。当方法应用于来自三个临床试验的数据时,这些结果得到了支持。

相似文献

1
Sample size calculations for single-arm survival studies using transformations of the Kaplan-Meier estimator.使用 Kaplan-Meier 估计量的变换进行单臂生存研究的样本量计算。
Pharm Stat. 2021 May;20(3):499-511. doi: 10.1002/pst.2090. Epub 2020 Dec 21.
2
Estimation of median survival time and its 95% confidence interval using SAS PROC LIFETEST.使用 SAS PROC LIFETEST 估计中位生存时间及其 95%置信区间。
J Biopharm Stat. 2024 May;34(3):366-378. doi: 10.1080/10543406.2023.2206481. Epub 2023 May 5.
3
A note on confidence intervals for the restricted mean survival time based on transformations in small sample size.基于小样本量变换的受限平均生存时间置信区间的一则注释
Pharm Stat. 2022 Mar;21(2):309-316. doi: 10.1002/pst.2170. Epub 2021 Sep 21.
4
A simple hybrid variance estimator for the Kaplan-Meier survival function.一种用于Kaplan-Meier生存函数的简单混合方差估计器。
Stat Med. 2005 Mar 30;24(6):827-51. doi: 10.1002/sim.1960.
5
Interval estimation of the attributable risk in case-control studies with matched pairs.配对病例对照研究中归因风险的区间估计。
J Epidemiol Community Health. 2001 Dec;55(12):885-90. doi: 10.1136/jech.55.12.885.
6
Sample size calculation for small sample single-arm trials for time-to-event data: Logrank test with normal approximation or test statistic based on exact chi-square distribution?针对事件发生时间数据的小样本单臂试验的样本量计算:采用正态近似的对数秩检验还是基于精确卡方分布的检验统计量?
Contemp Clin Trials Commun. 2019 Apr 13;15:100360. doi: 10.1016/j.conctc.2019.100360. eCollection 2019 Sep.
7
Sample size and power for the weighted log-rank test and Kaplan-Meier based tests with allowance for nonproportional hazards.加权对数秩检验和基于 Kaplan-Meier 的检验的样本量和功效,允许非比例风险。
Biometrics. 2020 Sep;76(3):939-950. doi: 10.1111/biom.13196. Epub 2019 Dec 23.
8
Improved precision in the analysis of randomized trials with survival outcomes, without assuming proportional hazards.在不假设风险比例的情况下,提高对具有生存结局的随机试验分析的精度。
Lifetime Data Anal. 2019 Jul;25(3):439-468. doi: 10.1007/s10985-018-9428-5. Epub 2018 Feb 28.
9
Assessment of gastric cancer survival: using an artificial hierarchical neural network.胃癌生存率评估:使用人工分层神经网络
Pak J Biol Sci. 2008 Apr 15;11(8):1076-84. doi: 10.3923/pjbs.2008.1076.1084.
10
Correcting for dependent censoring in routine outcome monitoring data by applying the inverse probability censoring weighted estimator.通过应用逆概率删失加权估计量对常规结局监测数据中的依存删失进行校正。
Stat Methods Med Res. 2018 Feb;27(2):323-335. doi: 10.1177/0962280216628900. Epub 2016 Mar 17.

引用本文的文献

1
Novel Usefulness of M2BPGi for Predicting Severity and Clinical Outcomes in Hospitalized COVID-19 Patients.M2BPGi在预测住院COVID-19患者病情严重程度和临床结局方面的新用途
Diagnostics (Basel). 2025 Apr 6;15(7):937. doi: 10.3390/diagnostics15070937.
2
Phase II trial of nab-paclitaxel plus ramucirumab in combination with nivolumab for unresectable advanced or recurrent gastric cancer after progression on first-line treatment including fluoropyrimidine, platinum, and anti-PD-1/PD-L1 antibody (PADDLE).纳武单抗联合白蛋白结合型紫杉醇和雷莫西尤单抗用于一线治疗(包括氟嘧啶、铂类和抗PD-1/PD-L1抗体)进展后的不可切除晚期或复发性胃癌的II期试验(PADDLE)。
BMC Cancer. 2025 Feb 4;25(1):201. doi: 10.1186/s12885-025-13591-5.
3
Diagnostic and Prognostic Utilities of Pancreatic Stone Protein in Patients with Suspected Sepsis.
胰石蛋白在疑似脓毒症患者中的诊断及预后价值
Diagnostics (Basel). 2024 Sep 19;14(18):2076. doi: 10.3390/diagnostics14182076.
4
Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: The multicenter phase 2 NICE-NEC trial (GETNE-T1913).纳武利尤单抗联合铂类双药化疗用于初治的晚期3级胃肠胰或来源不明的神经内分泌肿瘤患者:多中心2期NICE-NEC试验(GETNE-T1913)
Nat Commun. 2024 Aug 8;15(1):6753. doi: 10.1038/s41467-024-50969-8.
5
Single-arm clinical trials: design, ethics, principles.单臂临床试验:设计、伦理、原则。
BMJ Support Palliat Care. 2024 Dec 25;15(1):46-54. doi: 10.1136/spcare-2024-004984.
6
Utility of Presepsin and Interferon-λ3 for Predicting Disease Severity and Clinical Outcomes in COVID-19 Patients.降钙素原和干扰素-λ3在预测COVID-19患者疾病严重程度和临床结局中的应用
Diagnostics (Basel). 2023 Jul 14;13(14):2372. doi: 10.3390/diagnostics13142372.
7
Soluble ST2 as a Useful Biomarker for Predicting Clinical Outcomes in Hospitalized COVID-19 Patients.可溶性ST2作为预测住院COVID-19患者临床结局的有用生物标志物。
Diagnostics (Basel). 2023 Jan 10;13(2):259. doi: 10.3390/diagnostics13020259.
8
Stereotactic Radiosurgery for Lung Cancer with a Risk-Adapted Strategy Using the Volumetric Modulated Arc Therapy Technique: A Single Arm Phase II Study.采用容积调强弧形治疗技术的风险适应性策略立体定向放射外科治疗肺癌:单臂II期研究
Cancers (Basel). 2022 Aug 18;14(16):3993. doi: 10.3390/cancers14163993.
9
Survival analysis in cancer patients with hyponatremia: effectiveness of tolvaptan treatment.低钠血症癌症患者的生存分析:托伐普坦治疗的有效性
Int Urol Nephrol. 2022 Oct;54(10):2759. doi: 10.1007/s11255-022-03190-9. Epub 2022 Mar 26.
10
Prognostic Utility of Procalcitonin, Presepsin, and the VACO Index for Predicting 30-day Mortality in Hospitalized COVID-19 Patients.降钙素原、可溶性髓系细胞触发受体-1 和 VACO 指数对预测 COVID-19 住院患者 30 天死亡率的预后价值。
Ann Lab Med. 2022 Jul 1;42(4):406-414. doi: 10.3343/alm.2022.42.4.406.